Doxorubicin Global Market Report 2025

Doxorubicin is an anthracycline antibiotic used in cancer therapy due to its strong antitumor effects. It treats various cancers, including breast cancer, lung cancer, and hematological malignancies. The drug works by inhibiting DNA replication, which prevents cancer cells from dividing and growing.

Doxorubicin is available in two main forms lyophilized powder and doxorubicin injection. Lyophilized doxorubicin powder denotes a freeze-dried version of the chemotherapy drug, where the water content has been removed. Lyophilization is utilized to enhance preservation, ensuring the drug's stability and longevity. These formulations find application in the treatment of breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, among others, and are accessible through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The doxorubicin market research report is one of a series of new reports from The Business Research Company that provides doxorubicin market statistics, including the doxorubicin industry's global market size, regional shares, competitors with a doxorubicin market share, detailed doxorubicin market segments, market trends, and opportunities, and any further data you may need to thrive in the doxorubicin industry. This doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The doxorubicin market size has grown strongly in recent years. It will grow from $1.33 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to chemotherapy advancements, oncology treatment standard, clinical efficacy, patient survival rates, physician recommendations

The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to personalized medicine advancements, targeted drug delivery systems, immunotherapy combinations, genomic and biomarker research, precision oncology growth. Major trends in the forecast period include nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, cardioprotective interventions.

The forecast of 7.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology centers by inflating prices of doxorubicin chemotherapy drugs manufactured in Italy and India, resulting in delayed cancer treatments and higher chemotherapy infusion costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of cancer is propelling the doxorubicin market. Cancer encompasses a range of diseases characterized by the abnormal and uncontrolled growth of cells. Doxorubicin is a widely used antibiotic in chemotherapy that helps combat various cancers by damaging the DNA of cancer cells, thereby inhibiting their growth. The increasing incidence of cancer has led to a greater demand for doxorubicin. For example, the World Health Organization reported that in 2022, there were approximately 20 million new cancer cases and 9.7 million deaths worldwide. About 53.5 million people were living five years post-diagnosis, and roughly 1 in 5 individuals will develop cancer in their lifetime, with around 1 in 9 men and 1 in 12 women dying from the disease. Consequently, the growing number of cancer patients is driving the demand for doxorubicin.

The increase in genetic disorders is expected to drive the growth of the doxorubicin market in the future. Newborn screening is a physical examination conducted shortly after birth to check for specific health conditions, enabling healthcare professionals to identify and address particular needs before they cause illness. This screening can help identify infants at high risk for developing breast and ovarian cancer, allowing for early preventive measures using doxorubicin. For example, in 2022, the Texas Department of State Health Services reported that approximately 394,000 babies were screened, with 1,130 found to be affected by one of the newborn screening disorders. Therefore, the rise in genetic disorders is contributing to the growth of the doxorubicin market.

Major companies in the doxorubicin market are focused on developing innovative products, including chemotherapy medications, to improve treatment efficacy and minimize side effects for cancer patients. Chemotherapy drugs work by targeting and killing rapidly dividing cancer cells, but they can also affect some healthy cells, resulting in side effects. Recent advancements aim to enhance specificity and reduce these adverse effects. For example, in August 2024, Lupin Limited, an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection. This injection is used to treat advanced ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Its liposomal formulation enables targeted delivery, which helps reduce systemic side effects and improve patient tolerance. This approach enhances treatment efficacy, making it a vital option in oncology therapies.

Major players in the doxorubicin market are strategically focusing on innovative drug development to enhance their market standing. Notably, in May 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for the launch of Doxorubicin Hydrochloride Liposome Injection in the US market. This treatment targets ovarian and breast cancer, providing patients with a new therapeutic option. The approval process involved pre-clinical studies, clinical trials, and the submission of a New Drug Application (NDA) to the FDA to demonstrate the drug's safety and efficacy.

In March 2024, Johnson & Johnson, a US-based company engaged in the research, development, manufacturing, and sale of a diverse range of pharmaceutical products and medical devices, acquired Ambrx Biopharma, Inc. for $2 billion. This acquisition enhances Johnson & Johnson's capabilities in developing next-generation antibody-drug conjugates (ADCs), with a particular emphasis on targeting prostate cancer, an area of significant interest for the company. Ambrx Biopharma specializes in creating advanced ADCs for various cancer indications.

Major companies operating in the doxorubicin market include Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd

North America was the largest region in the doxorubicin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The doxorubicin market consists of sales of doxorubicin hydrochloride injections, adriamycin, doxil, myocet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Doxorubicin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on doxorubicin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for doxorubicin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The doxorubicin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Formulation: Lyophilized Powder; Doxorubicin Injection
• 2) By Application: Breast Cancer; Kidney Cancer; Liver Cancer; Sarcoma; Ovarian Cancer; Lung Cancer; Leukemia; Multiple Myeloma; Other Applications
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Lyophilized Powder: Reconstituted Formulations; Freeze-Dried Preparations
• 2) By Doxorubicin Injection: Ready-To-Use Solutions; Concentrated Solutions For Dilution; Liposomal Doxorubicin Injections
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Hikma Pharmaceuticals; Mylan Pharmaceuticals Inc.; Accord Healthcare Ltd.; TTY Biopharm Company Limited; Cadila Pharmaceuticals; Neon Laboratories Limited; APP Pharmaceuticals Manufacturing LLC; Sun Pharmaceutical Industries Ltd.; Transo-Pharm Handels GmbH; LGM Pharma; Zhejiang Hisun Pharma; Actavis Pharma; Celon Laboratories Limited; Samarth Life Sciences Pvt. Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.